Clinical trials: Internuclear Ophthalmoplegia
Multiple Sclerosis, Internuclear Ophthalmoplegia
Study and Treatment of Visual Dysfunction and Motor Fatigue in Multiple Sclerosis
Primary fatigue represents a major cause of disability in patients with multiple sclerosis (MS), being reported in about 90% of cases.
- Conditions
- Multiple Sclerosis, Internuclear Ophthalmoplegia, Fatigue
- Trial name
- NCT02391961
- Testing
- Dalfampridine
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- VA Office of Research and Development